Over 1 billion people, including 500 million children, are affected by Neglected Tropical Diseases (NTDs), a group of diseases that disproportionally prevail in tropical and subtropical countries. Most people suffering from these diseases are the poorest of the poor, living in remote areas of Sub-Sahara African, South-East Asian, and Latin American countries. NTDs lead to serious economic consequences for patients, families and entire communities and pose serious social difficulties such as stigma and discrimination, especially for girls and women.
Takeda’s partnership with DNDi aims to expand neglected patient’s access to quality diagnosis and treatment in disease-endemic countries, including in peripheral settings, and consequently prevent disease progression while saving lives. DNDi targets five NTDs: sleeping sickness, Chagas disease, leishmaniasis, onchocerciasis and mycetoma, that are characterized by significant morbidity and/or mortality and have been prioritized due to the current limited availability and accessibility of effective diagnostic and treatment. This partnership contributes to ensuring Universal Health Coverage (UHC) as the foundation for achieving the health objectives of the Sustainable Development Goals (SDGs), with access to adequate medical tools, including new treatments, as priorities in the global community’s pursuit of ending Neglected Tropical Diseases by 2030.
Partner: DNDi (Drugs for Neglected Diseases initiative)
Budget: 1 billion yen
Term: 5 years
Area: 16 countries across Africa, Asia, and South America
Empower Cities to Deliver Quality and Equitable Cancer Care
Transforming the Lives of Children with Serious Illness, and Their Families
Immunization and Universal Health Coverage
Investment in Innovation and Frontier Technology